Stratos Wealth Partners
MBRX icon

Stratos Wealth Partners’s Moleculin Biotech MBRX Stock Holding History

Stratos Wealth Partners’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$18.8K Buy
+1,877
New +$41.8K ﹤0.01% 1707

Other funds holding MBRX

Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $273B AUM 15.34% 1-Year Est. Return
Newbridge Financial Services Group
Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Danske Bank
Danske Bank Copenhagen K, Denmark $50.1B AUM 35.17% 1-Year Est. Return

Stratos Wealth Partners's MBRX Position: Q3 2026 in Review

Stratos Wealth Partners opened a new position in Moleculin Biotech (MBRX) in Q3 2026: 1,877 shares worth $18.8K. The stake represents ﹤0.01% of the portfolio and ranks #1707 among its holdings.

7 funds tracked by Wall St. Rank hold MBRX as of Q3 2026.

  • Stratos Wealth Partners held 1,877 shares of Moleculin Biotech worth $18.8K as of Q3 2026.
  • Moleculin Biotech was a new Stratos Wealth Partners position in Q3 2026.
  • Moleculin Biotech made up ﹤0.01% of Stratos Wealth Partners's portfolio in Q3 2026, its #1707 holding.
  • 7 funds tracked by Wall St. Rank held Moleculin Biotech as of Q3 2026.

Based on Stratos Wealth Partners's 13F filing for Q3 2026, filed 13 Nov 2026.